Rational design for controlled release of Dicer-substrate siRNA harbored in phi29 pRNA-based nanoparticles

Small interfering RNA (siRNA) for silencing genes and treating disease has been a dream since ranking as a top Breakthrough of the Year in 2002 by Science. With the recent FDA approval of four siRNA-based drugs, the potential of RNA therapeutics to become the third milestone in pharmaceutical drug d...

Descripción completa

Detalles Bibliográficos
Autores principales: Binzel, Daniel W., Guo, Songchuan, Yin, Hongran, Lee, Tae Jin, Liu, Shujun, Shu, Dan, Guo, Peixuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463318/
https://www.ncbi.nlm.nih.gov/pubmed/34589275
http://dx.doi.org/10.1016/j.omtn.2021.07.021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463318/
https://www.ncbi.nlm.nih.gov/pubmed/34589275
http://dx.doi.org/10.1016/j.omtn.2021.07.021

Ejemplares similares